Fosaprepitant for Injection
Chemotherapy-induced nausea and vomiting
ApprovedActive (Launched)
Key Facts
Indication
Chemotherapy-induced nausea and vomiting
Phase
Approved
Status
Active (Launched)
Company
About Praxgen Pharmaceuticals
Praxgen Pharmaceuticals, founded in 2016 and headquartered in San Diego with key operations in New Jersey, is a private, commercial-stage generic drug developer. The company has a strategic focus on complex generics, with over 40 products in development and a track record of ANDA approvals and product launches, such as generic Medrol and Fosaprepitant. Leveraging a hybrid model of in-house R&D and external manufacturing partnerships, Praxgen aims to capture value in high-barrier, high-market-size generic drug segments while navigating the competitive and regulatory pressures inherent to the industry.
View full company profileTherapeutic Areas
Other Chemotherapy-induced nausea and vomiting Drugs
| Drug | Company | Phase |
|---|---|---|
| Akynzeo (netupitant/palonosetron) | Angelini Pharma | Approved |